News

Achillion has initiated dosing in a phase-I clinical trial of ACH-1625, a protease inhibitor for the treatment of hepatitis-C virus (HCV) infection. ACH-1625 is a strong small molecule

Teva and its partner, Antares have received approval of a Supplemental New Drug Application (sNDA), which added needle-free injection to its Tev-Tropin, human growth hormone (hGH) drug label.

AMAG Pharmaceuticals has announced that it has not received an action letter from FDA for Feraheme (ferumoxytol) Injection, for the treatment of iron deficiency anemia in adult chronic

Evotec has completed first phase-I study with P2X7 receptor antagonist, EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat

Access has commenced commercial launch of MuGard in Greece. Under a license from Access, SpePharm is responsible for manufacturing, regulatory approval and commercialization in 27 countries of Europe.

Bayer Schering Pharma (Bayer Schering) has signed a license agreement with Celera, which provides Bayer Schering with access to five cancer-related targets for therapeutic development and in-vivo diagnostic

The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in nocturia patients, as determined by increased osmolality and decreased urine output.

AcelRx has reported positive results from the second phase-II clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs. It is to be used for the

Novartis has initiated phase-III clinical study with NVA237, a once-daily, muscarinic antagonist (Lama), for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation